By InvitationEarly Phase 1

COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO

Pakistan60 participantsStarted 2025-05-01

Plain-language summary

Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed

Who can participate

Age range15 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Localized vitiligo Age 15 to 70years Body surface upto 20% Stable more than 3 months Exclusion Criteria: * • Pregnant or lactating female patients. * Skin malignancy or any other malignant skin condition. * Photo induced or photo aggravated dermatosis like (SLE, photodermatitis, rosacea, psoriasis, pemphigus vulgaris) along with vitiligo. * Prior history of allergy to tacrolimus or calcipotriol. * Other form of treatment for vitiligo within at least 1 month.

What they're measuring

VASI improvement upto 50%

Timeframe: 3 months

Trial details

NCT IDNCT06880042

SponsorDr ayesha wahid

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2025-06-30

View on ClinicalTrials.gov More Vitiligo - Macular Depigmentation trials